GE Healthcare acquired the license to a new molecular imaging agent that could be useful in diagnosing heart attacks and monitoring how well tumors respond to drugs.

Developed by Ming Zhao, Ph.D., an assistant professor in biophysics at the Medical College of Wisconsin in Milwaukee, Wis., the tracer binds to dying cells, making it useful for doctors who want to detect damage to the heart, figure out if a tumour is weakening in response to treatment, or find hidden internal injuries. So if tagged with a gamma-based radioactive tracer, such as an isotope of technetium, or even a fluorolabel, the molecule could becoming visible to the appropriate nuclear medicine modality, such as PET or SPECT.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related Corporate Updates


whatsapp--v1